Stroke With Transfusions Changing to Hydroxyurea (SWiTCH)

Blood

Volumn 119, Issue 17, 2012, Pages 3925-3932

  Ware, Russell E ^a   Helms, Ronald W ^b  

^a TEXAS CHILDREN S HOSPITAL   (United States)

^b RHO INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERASIROX; HEMOGLOBIN; HYDROXYUREA;

ARTICLE; BLOOD TRANSFUSION; CHILD; CONTROLLED STUDY; FEMALE; HUMAN; IRON CHELATION; IRON OVERLOAD; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PHLEBOTOMY; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SICKLE CELL ANEMIA; STROKE;

EID: 84860348352     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-11-392340     Document Type: Article

References (35)

1. Ohene-Frempong K. Stroke in sickle cell disease: demographic, clinical, and therapeutic considerations. Semin Hematol. 1991;28(3):213-219.
2. Powars D, Wilson B, Imbus C, Pegelow C, Allen J. The natural history of stroke in sickle cell disease. Am J Med. 1978;65(3):461-471. (Pubitemid 8397664)
3. Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood. 1998;91(1): 288-294. (Pubitemid 28018756)
4. Balkaran B, Char G, Morris JS, et al. Stroke in a cohort of patients with homozygous sickle cell disease. J Pediatr. 1992;120(3):360-366.
5. Moohr JW, Wilson H, Pang EJ-M. Strokes and their management in sickle cell disease. In: Fried W, ed. Comparative Clinical Aspects of Sickle Cell Disease. Amsterdam, The Netherlands: Elsevier North Holland; 1982:101-111.
6. Rosse WF, Telen MJ, Ware RE. Transfusion Support for Patients with Sickle Cell Disease. Bethesda, MD: AABB Press; 1998;51-52.
7. Pegelow CH, Adams RJ, McKie V, et al. Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. J Pediatr. 1995;126(6):896-899.
8. Scothorn DJ, Price C, Schwartz D, et al. Risk of recurrent stroke in children with sickle cell disease receiving blood transfusion therapy for at least five years after initial stroke. J Pediatr. 2002; 140(3):348-354. (Pubitemid 34289713)
9. Wilimas J, Goff JR, Anderson JR Jr, Langston JW, Thompson E. Efficacy of transfusion therapy for one to two years in patients with sickle cell disease and cerebrovascular accidents. J Pediatr. 1980;96(2):205-208. (Pubitemid 10129397)
10. Wang WC, Kovnar EH, Tonkin IL, et al. High risk of recurrent stroke after discontinuance of five to twelve years of transfusion therapy in patients with sickle cell disease. J Pediatr. 1991;118(3): 377-382.
11. Rosse WF, Gallagher D, Kinney TR, et al. Transfusion and alloimmunization in sickle cell disease. The Cooperative Study of Sickle Cell Disease. Blood. 1990;76(7):1431-1437. (Pubitemid 20342762)
12. Castellino SM, Combs MR, Zimmerman SA, Issitt PD, Ware RE. Erythrocyte autoantibodies in paediatric patients receiving transfusion therapy: frequency, characteristics, and significance. Br J Haematol. 1999;104(1):189-194. (Pubitemid 29037039)
13. Nietert PJ, Abboud MR, Silverstein MD, et al. Bone marrow transplantation versus periodic prophylactic blood transfusion in sickle cell patients at high risk of ischemic stroke: a decision analysis. Blood. 2000;95(10):3057-3064. (Pubitemid 30321154)
14. Harmatz P, Butensky E, Quirolo K, et al. Severity of iron overload in patients with sickle cell disease receiving chronic red blood cell transfusion therapy. Blood. 2000;96(1):76-79. (Pubitemid 30456453)
15. Ballas SK. Iron overload is a determinant of morbidity and mortality in adult patients with sickle cell disease. Semin Hematol. 2001;38(1 suppl 1):30-36. (Pubitemid 32110270)
16. Strouse JJ, Lanzkron S, Beach MC, et al. Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children. Pediatrics. 2008;122(6):1332-1342.
17. Lanzkron S, Strouse JJ, Wilson R, et al. Systematic review: hydroxyurea for the treatment of adults with sickle cell disease. Ann Intern Med. 2008;148(12):939-955. (Pubitemid 351860826)
18. Ware RE, Steinberg MH, Kinney TR. Hydroxyurea: an alternative to transfusion therapy for stroke in sickle cell anemia. Am J Hematol. 1995;50(2): 140-143.
19. Ware RE, Zimmerman SA, Schultz WH. Hydroxyurea as an alternative to blood transfusions for the prevention of recurrent stroke in children with sickle cell disease. Blood. 1999;94(9):3022-3026. (Pubitemid 29512706)
20. Ware RE, Zimmerman SA, Sylvestre PB, et al. Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy. J Pediatr. 2004;145(3):346-352. (Pubitemid 39165683)
21. Ware RE, Schultz WH, Yovetich N, et al. Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload. Pediatr Blood Cancer. 2011;57(6):1011-1017.
22. Zimmerman SA, Schultz WH, Davis JS, et al. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood. 2004;103(6):2039-2045. (Pubitemid 38326218)
23. Heeney MM, Ware RE. Hydroxyurea for children with sickle cell disease. Pediatr Clin North Am. 2008;55(2):483-501. (Pubitemid 351447270)
24. Ware RE. How I use hydroxyurea to treat young patients with sickle cell anemia. Blood. 2010; 115(26):5300-5311.
25. Hulbert ML, McKinstry RC, Lacey JL, et al. Silent cerebral infarcts occur despite regular blood transfusion therapy after first strokes in children with sickle cell disease. Blood. 2011;117(3):772-779.
26. Ruggeri M, Finotto S, Fortuna S, Rodeghiero F Treatment outcome in a cohort of young patients with polycythemia vera. Intern Emerg Med. 2010; 5(5):411-413.
27. Angelucci E, Muretto P, Lucarelli G, et al. Phlebotomy to reduce iron overload in patients cured of thalassemia by bone marrow transplantation. Italian Cooperative Group for Phlebotomy Treatment of Transplanted Thalassemia Patients. Blood. 1997;90(3):994-998. (Pubitemid 27314132)
28. St Pierre TG, Clark PR, Chua-Anusorn W, et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood. 2005;105(2):855-861. (Pubitemid 40070775)
29. Noetzli LJ, Carson SM, Nord AS, Coates TD, Wood JC. Longitudinal analysis of heart and liver iron in thalassemia major. Blood. 2008;112(7): 2973-2978.
30. * magnetic resonance imaging of the liver in patients with iron overload. Blood. 2009;113(20): 4853-4855.
31. Greenway A, Ware RE, Thornburg CD. Long-term results using hydroxyurea/phlebotomy for reducing secondary stroke risk in children with sickle cell anemia and iron overload. Am J Hematol. 2011;86(4):357-361.
32. Enninful-Eghan H, Moore RH, Ichord R, Smith-Whitley K, Kwiatkowski JL. Transcranial Doppler ultrasonography and prophylactic transfusion program is effective in preventing overt stroke in children with sickle cell disease. JPediatr. 2010; 157(3):479-484.
33. Bernaudin F, Verlhac S, Arnaud C, et al. Impact of early transcranial Doppler screening and intensive therapy on cerebral vasculopathy outcome in a newborn sickle cell anemia cohort. Blood. 2011; 117(4):1130-1140.
34. Adams RJ, Brambilla D. Optimizing primary stroke prevention in sickle cell anemia (STOP 2) trial investigators. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N EnglJ Med. 2005;353(26):2769-2778.
35. Wang WC, Ware RE, Miller ST, et al; the BABY HUG Investigators. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet. 2011;377(9778):1663-1672.